Galderma Group AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on the stock and has a CHF160.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that highlight Galderma Group AG’s strong performance and potential for growth. The company’s third-quarter sales exceeded expectations by 4%, with a notable 21% increase at constant exchange rates, surpassing the consensus forecast of 15.6%. This growth was primarily driven by the success of their Injectable Aesthetics and Nemluvio products, which outperformed market expectations.
Moreover, Nemluvio’s sales were particularly impressive, coming in 11% above consensus, supported by its expanding international presence and significant contributions from atopic dermatitis treatments. The company’s overall performance in Therapeutic Dermatology exceeded expectations by 7%, which, combined with the potential for mid-single-digit upgrades to the 2025 outlook, suggests a positive trajectory for Galderma Group AG. These factors contribute to the expectation of a mid-single-digit increase in share value, justifying the Buy rating.
In another report released on October 20, Barclays also maintained a Buy rating on the stock with a CHF140.00 price target.